+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06758375

Low-dose Teclistamab After Initial VRd Therapy for Newly Diagnosed Multiple Myeloma Patients

Led by Hospital Universitario Dr. Jose E. Gonzalez · Updated on 2025-03-20

10

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a low-dose, limited-duration teclistamab treatment as a consolidation therapy for patients newly diagnosed with multiple myeloma NDMM. This single-arm, open-label phase 2 study aims to understand how well this treatment works following initial therapy with three cycles of a combination regimen called VRd, which includes bortezomib, lenalidomide, and dexamethasone. Participants will first receive three cycles of the VRd induction therapy. Afterward, they will receive four doses of teclistamab at 1.0 mgkg given under the skin. Four weeks after the last teclistamab dose, their clinical response will be evaluated using standard criteria. Those achieving complete response CR or better will undergo further testing for minimal residual disease MRD. Depending on MRD results and risk status, participants will either be monitored for 18 months or receive biweekly bortezomib maintenance. Those with less than CR may receive additional teclistamab doses or exit the study to continue standard care. Throughout the study, participants will be monitored for their response to treatment, including assessments of disease status and side effects. The primary outcome is the general response 18 months after the last teclistamab dose. Secondary outcomes include response duration and adverse events over the same period. The study involves follow-up care based on individual responses and continued monitoring for up to 18 months after treatment.

CONDITIONS

Brief Title

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Research Team

D

David Gomez-Almaguer, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here